epithalon dosing protocol subcutaneous Dosage Calculator and Chart Epithalon Benefits and Research Applications

mean age 40[SD 11.1], 59% female): 37 presymptomatic mutation-carriers (no symptomatic ICH), three symptomatic mutation-carriers (one symptomatic ICH), eight 50%-at-risk participants and 18 controls Among 37 presymptomatic mutation-carriers, 23(62%) had WMH in a multi-spot pattern, 28(76%) severe CSO-EPVS, 17(46%) microbleeds, and 8(22%) macrobleeds

IGF-1 LR3 is a recombinant 83-residue IGF-1 analog with arginine substituted for glutamic acid at position 3 and an additional 13-residue N-terminal extension

Frequency of Treatments: Many clients benefit from weekly or bi-weekly injections depending on their energy and wellness goals

Compared to Other GH Fragments: AOD-9604 represents a specific fragment (amino acids 176-191 plus N-terminal tyrosine)